The unique antigenic determinants (idiotype (Id)) of the immunoglobulin secreted by myeloma tumor can serve as a tumor-specific antigen for active immunotherapy. Our objective was to induce tumor-specific T-cell immunity in bone marrow transplant (BMT) donors to enhance antitumor effects of allografts. We vaccinated five HLAmatched sibling donors with myeloma Id proteins isolated from recipient plasma before bone marrow harvest. Recipients were administered booster Id immunizations following transplantation. Vaccination induced donor Id and carrier-specific cellular and/or humoral immune responses. Two recipients died within 30 days of BMT from transplant-related complications. Id and carrierspecific T-cell responses were detected in all three remaining patients post-, but not pre-BMT and persisted for 18 months. All three surviving patients converted from partial to complete responses following BMT. Two of the three patients remain disease-free 7 years and 8 years after BMT, and the third died of renal failure after 5.5 years while in complete remission from myeloma. Our results suggest that myeloma Id vaccination induces specific T-cell immunity in healthy donors which may be transferable by BMT, is associated with prolonged disease-free survival of recipients, and may represent a general strategy to enhance graft-versus-tumor effect in other malignancies for which defined tumor-specific antigens exist.
allogeneic
Despite the use of high-dose therapy (HDT) followed by autologous stem cell transplantation median survival has not improved beyond 4-5 years for multiple myeloma (MM) and even tandem autografts do not appear to be curative for this disease. [1] [2] [3] [4] This is probably due to the failure to completely eradicate the tumor cells from the patients and autografts. As an alternative, allogeneic transplantation provides a tumor-free stem cell source, mediates a potential graft-versus-myeloma (GVM) effect, and has been shown to induce prolonged disease-free survival in a small percentage of patients. [5] [6] [7] However, the majority of patients relapse following allogeneic transplantation. Attempts to enhance the GVM effect by donor lymphocyte infusions have resulted in increased incidence of graft-versus-host disease (GVHD). 8, 9 Therefore, strategies to enhance the specific antitumor effect of the graft without increasing the risk of GVHD are needed to improve the outcome in allotransplant recipients. To this end, we have vaccinated allotransplant donors against a defined, patient tumor-derived antigen prior to bone marrow harvest. The objective of this strategy is to induce tumor antigen-specific immunity in donors and to transfer this immunity to the recipient by bone marrow transplantation (BMT). We demonstrated previously that tumor antigen-specific immunity induced in murine donors prior to bone marrow harvest could confer protection against lethal tumor challenge in BMT recipients. 10, 11 MM is characterized by clonal proliferation of plasma cells all of which secrete the same immunoglobulin molecule (M-protein). The variable regions of the heavy and light chains of a given immunoglobulin molecule contain unique sequences, termed idiotype (Id) that can be recognized as an antigen. Therefore, the Id of the MM can serve as a tumor-specific antigen and has been exploited as a target for active specific immunotherapy in animal models. [12] [13] [14] [15] [16] [17] In addition, the M-protein can be easily isolated from human plasma and purified into a highly refined, safe protein vaccine. Individualized Id vaccines have been evaluated in a number of clinical trials in myeloma and lymphoma patients. [18] [19] [20] [21] [22] [23] [24] Furthermore, Id-specific cytotoxic T-cell lines generated from myeloma patients by repeated in vitro stimulation with Id pulsed dendritic cells specifically recognized and lysed autologous primary myeloma cells, 25, 26 validating human myeloma cells as targets of an Id-specific T-cell response.
Transfer of antigen-specific humoral and cellular immunity against infectious disease pathogens from healthy donors to allotransplant recipients has been previously demonstrated in humans. [27] [28] [29] Furthermore, we previously demonstrated in a single patient with myeloma that tumor antigen-specific immunity, induced in the HLA-matched sibling donor by myeloma Id vaccination, could be transferred to the recipient by allogeneic BMT as a result of Id vaccination of the donor alone. 18 Independently, successful transfer of donor Id-specific immunity with donor lymphocyte infusion has been described in another myeloma patient. 30 In the current pilot study, we build upon this initial experience by combining donor and recipient Id vaccination to optimize clinical effect with this approach in five additional HLA-matched donor-recipient pairs.
Patients and methods

Patients
After obtaining signed informed consent, five MM patients were enrolled in this investigational review board-approved clinical trial under an approved FDA IND application (BB-IND 5779). Eligible patients were less than 60 years old, with IgG or IgA MM who attained at least a partial response prior to the transplantation. Patients had received only 3-4 courses of VAD, high-dose cyclophosphamide, and/or one autologous transplant prior to study entry (Table 1) . Eligibility required a life expectancy of 48 weeks, Karnofsky performance status of 470%, absence of co-morbid illnesses that would preclude bone marrow transplant, and adequate cardiac, renal, pulmonary, and hepatic functions. All patients underwent a plasmapheresis during periods of active disease to obtain Id protein for vaccine production. The M-protein concentration in the harvested plasma had to be 490% of the total immunoglobulin of the corresponding isotype for study eligibility.
Donors
Five healthy HLA-matched sibling donors were enrolled on the study after obtaining signed informed consent. Two donors, D4 and D5 were identical twins of the recipients, R4 and R5 respectively (Table 1) .
Vaccine formulation
Tumor immunoglobulin protein (Id) was isolated from each patient's plasma by affinity chromatography 25 and chemically conjugated to the carrier molecule KLH (Biomira, Edmonton, Canada) and analyzed as previously described. 18, 22 The vaccine formulation consisted of either Id (0.5 mg) mixed with GM-CSF (250 mg/m 2 ) or Id conjugated to KLH (0.5 mg) and mixed with the same amount of GM-CSF. Vaccine þ GM-CSF was administered subcutaneously for three doses to donors and six doses to recipients (Figure 1 ). All donors received Id-KLH þ GM-CSF for vaccine 1 and Id þ GM-CSF for vaccines 2 and 3. All recipients received Id-KLH þ GM-CSF for vaccines 1, 4, 5, and 6; and Id þ GM-CSF for vaccines 2 and 3. For each course, three additional doses of GM-CSF (250 mg/m 2 ) were administered on days 2, 3 and 4 in close proximity to the vaccination site. All recipients started vaccination at least two weeks after the discontinuation of prior chemotherapy and/or steroids, and after recovery from all hematologic (normal absolute neutrophil count and platelets) and grade 3 or 4 nonhematologic toxicity from prior therapy. No criteria were set for absolute lymphocyte count prior to vaccination.
Vaccinations
All vaccinations were administered at the National Cancer Institute, National Institutes of Health, Bethesda, MD. All donors received three vaccinations prior to the bone marrow harvest. All recipients were vaccinated thrice prior to the BMT, but only patients R4 and R5 received all three scheduled booster vaccinations post-BMT. Patient R1 could not be vaccinated after one post-BMT booster immunization due to the development of steroid dependent chronic GVHD. Patient R2 died on day þ 26 from renal failure and veno-occlusive disease and patient R3 expired on day þ 22 due to intracranial and pulmonary hemorrhage. Therefore, these two patients did not receive any post-BMT immunizations.
Bone marrow transplantation
2 weeks after the final immunization, the patient and donor were transferred to the University of Arkansas for Medical Sciences, Little Rock, AR for the bone marrow transplant procedure. The preparative regimen consisted of hyperfractionated total body irradiation (1375 cGy over 4 days from days À10 to À7), thiotepa 5 mg/kg/day i.v. over 4 h on days À5 and À4, and cyclophosphamide 60 mg/kg/day i.v. over 1 h on days À3 and À2. For patients not eligible to receive total body irradiation, a total busulfan dose of 14 mg/kg was administered orally over 4 days (days À7 to À4) and cyclophosphamide was administered at 60 mg/kg/ day i.v. over 1 h on days À3 and À2. Approximately 24-36 h after the completion of treatment with cyclophosphamide, 2-3 Â 10 8 nucleated cells/kg of marrow was harvested from the donor under general anesthesia, filtered through 200 mM wire mesh, and infused into the recipient. G-CSF was started on day þ 1 and GVHD prophylaxis consisted of a combination of cyclosporine (started on day À1) and methotrexate (started on day þ 1).
Clinical monitoring
Patients were monitored for myeloma by serial measurement of M-protein in the serum and urine, bone marrow aspirate and biopsy and skeletal surveys. Serum and urine protein electrophoresis with immunofixation was performed once a month for the first year, every three months for the second year and every 6 months thereafter. Complete response was defined as absence of M-protein in serum and urine by immunofixation, less than 5% plasma cells in bone marrow by differential and less than 1% monoclonal plasma cells by DNA-cIg flow cytometry, and with no change in size or number of lytic bone lesions for a minimum of 2 months. Partial response was defined as reduction of serum M-protein by 75%, decrease in BenceJones proteinuria by 490% or excretion of o200 mg in 24 h, less than 5% plasma cells in bone marrow by differential and less than 1% monoclonal plasma cells by DNA-cIg flow cytometry, and with no change in size or number of lytic bone lesions for a minimum of 2 months.
Blood samples
Blood samples were obtained from recipients and donors at the time of each vaccination and one month after the final vaccination. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient separation with Ficoll Isopaque (ICN Biomedicals Inc., Aurora, OH, USA) and used fresh for immunological assays.
Proliferation assay
Fresh PBMC were plated in a 96-well microwell plate at a concentration of 2 Â 10 5 cells/well in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 1 mM L-glutamine (Invitrogen), nonessential amino acids, 1 mM sodium pyruvate (BioWhittaker, Walkersville, MD, USA), and 10 mg/ml gentamicin (BioWhittaker). Cells were incubated in the presence or absence of autologous Id (derived from patient), or isotype-matched irrelevant Id (50 mg/ml) and/or KLH. After 6 days of incubation at 371C in 5% CO 2 humidified incubator, 3 H-thymidine (1 mCi/well) was pulsed for 18-24 h and counted on a beta-counter. Results were expressed as mean (s.d.) counts per min of triplicate wells. A patient was considered to have a positive Id-specific immune response, if the mean count per minute response to the autologous Id was twice or more than the negative controls.
Cytokine induction assay
To assess Id-specific cytokine production, fresh PBMC obtained at various time points (1 Â 10 6 /ml) were cultured or BMT, respectively. In addition, the recipients were given booster immunizations at 3 , 4 and 6 months after the transplant. GM-CSF was administered in close proximity to the vaccination site for 4 days with each vaccine cycle.
in Clicks medium (Sigma, St Louis, MO, USA) supplemented with 10% FBS (Hyclone), 2% human AB serum (Gemini, Calabasas, CA, USA), and 1 mM sodium pyruvate (BioWhittaker), 20 mM HEPES buffer (Invitrogen), 50 mM b-mercaptoethanol (Sigma), 100 U/ml penicillin þ 100 mg/ ml streptomycin (Invitrogen), and 10 mg/ml gentamicin (BioWhittaker) in a 48-well plate (Corning, Inc., Corning, NY, USA) in the absence or presence of patient-specific Id protein (50 mg/ml) or control isotype-matched irrelevant Id proteins and/or KLH. 25 Supernatants were harvested after 6 days of incubation at 371C in 5% CO 2 humidified incubator and cytokine production (GM-CSF and TNFa) was measured by ELISA using Quantikine kits (R&D Systems, Minneapolis, MN, USA). A patient was considered to have a positive Id-specific immune response, if the cytokine production in response to the autologous Id was twice or more than the negative controls.
Anti-KLH antibody assay
The anti-KLH antibody was measured by ELISA. Prevaccine and postvaccine serum samples were serially diluted over wells in a microtiter plate that had been coated with KLH. Bound antibody was detected by KLH-biotin followed by horseradish-peroxidase streptavidin. A positive response was defined when the anti-KLH antibody titer increased four-fold or higher.
Anti-Id antibody assay
The anti-Id antibody responses were measured by ELISA as previously described. 22 A microtiter plate was coated with patient-specific Id protein or control isotype-matched irrelevant Id proteins. Prevaccine and postvaccine serum samples were serially diluted over the Id and irrelevant Id-coated wells. Bound antibody was detected with horseradish peroxidase-goat anti-human light chain or heavy chain antibodies (Caltag, Burlingame, CA, USA) directed against the light-chain or heavy-chain not present in the autologous Id. A positive response was defined when the anti-Id antibody titer increased four-fold or higher.
Results
Clinical course and toxicity
All recipients were in partial remission prior to transplantation. Two recipients (R2 and R3) succumbed to early post-BMT complications before day þ 30 and were therefore not evaluable for transfer of immunity. The remaining three recipients received the planned booster vaccinations beginning 100 days post transplantation and converted to CR (Table 1 ). Chimerism analysis revealed that lymphoid cells were of 100% donor origin by day þ 97 in patient R1 (data not shown). This patient developed steroid-dependent chronic skin GVHD 3 months after the transplant and died of renal failure while in complete remission 5.5 years after the transplant. Chimerism analysis could not be performed in patients R4 and R5, as they received syngeneic twin transplants. Patients R4 and R5 remain in complete remission for 8 and 7 years, respectively, after transplantation.
The vaccine was well tolerated by all donors and recipients. Erythema and induration lasting up to 1-2 weeks were noted at the sites of injections in all patients. There were no serious adverse events due to the vaccine. Importantly, donor immune serum was evaluated for autoimmune responses against Ig constant region or other determinants by C1q binding assay, total complement, and Raji cell assay, but no laboratory or clinical evidence of autoimmunity was detected. With median follow-up of 8 years in the five donors, no long-term toxicity has been observed in any immunized donor.
Antigen-specific T-cell and antibody responses were induced in all donors by immunization
Fresh donor PBMC obtained before and after vaccination were tested for specific recognition of KLH carrier and recipient myeloma Id proteins in standard proliferation assays. Postvaccine, but not prevaccine, PBMC from all donors proliferated significantly in response to KLH (Figure 2a) , and KLH antibody responses were detected in all donors by ELISA (data not shown). Of primary interest, post , but not prevaccine PBMC from donors D1, D4 and D5 proliferated and produced significant amounts of TNFa and/or GM-CSF in response to their respective recipients' Id proteins (Figure 2b-e) . The lack of reactivity against panels of other myeloma Id proteins of irrelevant Id suggests that the immune responses were specific for the unique recipient Id protein (Figure 2b -e; single representative irrelevant Ids shown). Although Id-specific cellular responses could not be definitively established in donors D2 and D3 (data not shown), significant anti-Id antibody titers were detected in these donors as well as in donor D1 (Figure 2f ). The absence of binding to irrelevant Id proteins suggested that the induced antibody responses were specific for the Id with which the donor was vaccinated. Moreover, while KLH-specific T-cell responses were observed after only one vaccination, Id-specific T-cell responses required three vaccinations (Figure 2b-d) . Taken together, these data suggest specific vaccination of all five donors against recipient myeloma proteins.
KLH-specific immunity was transferred from donors to recipients
Fresh PBMC obtained from myeloma patients, pre-and post-BMT were first tested for recognition of the carrier. Patient R5 was the most clearly informative. The absence of a KLH-specific T-cell response or antibody response in-patient R5 before the transplant, combined with the detection of both responses post-BMT, both before and after booster immunization at 3 months, suggests that KLH-specific immunity was transferred from donor to recipient (Figure 3a and b) . Among the other two patients, who survived BMT, in-patient R1, KLH T-cell and antibody responses were detected pre-and post-BMT, prior to booster immunization ( Figure 3c ). As this patient's lymphoid cells were of 100% donor origin by day þ 97 (data not shown) it is likely that the KLH-specific T cells were also of donor origin. Patient R4 had no clear KLH T cell or antibody response until after booster vaccination post-BMT (Figure 3d and e) . Thus, the relative contribution of donor immunity to the vigorous KLH responses detected post BMT in this patient cannot be definitively determined. To summarize, KLH-specific T cell and antibody responses were detected in three (R1, R2, and R3) of five recipients pre BMT and all three surviving recipients (R1, R4, and R5) post-BMT. H-thymidine (1 mCi/well) was pulsed for 18-24 h and counted on a beta-counter. Results were expressed as mean (s.d.) counts per minute of triplicate wells (a-d). Cytokine production in the supernatants was measured by ELISA (e). The anti-Id antibody response was measured by ELISA (f). Prevaccine and postvaccine (obtained after the first, second, and third vaccinations) serum samples from donor D2 were serially diluted over the Id (isotype IgAk) and isotype matched irrelevant Id coated wells (Irrel. Id). Bound antibody was detected with horseradish peroxidase-goat anti-human IgG antibody. The asterisk indicates samples with a positive immune response.
Id-specific T-cell immunity was detected in the recipients post-BMT Concurrently, fresh PBMC obtained from recipients were tested for recognition of autologous Id protein by proliferation and cytokine induction. Cellular proliferative responses were detectable in all three patients (R1, R4, and R5) post-but not pre-BMT (Figure 4a and b) . The specificity of these responses for Id was confirmed by the lack of significant proliferation (Figure 4a irrelevant Ids. In at least one patient, Id-specific responses persisted beyond 18 months after the completion of booster immunizations (Figure 4a ). The detection of significant Idspecific cellular responses in all three recipients after a single post-BMT booster vaccination is consistent with the conclusion that these responses were donor-derived ( Figure  4a and b). This conclusion is further supported by the observation that recipient R1 had 100% donor lymphoid chimerism prior to the post-BMT booster vaccination. Humoral responses to Id were not detectable in any of the five recipients either pre-or post-BMT.
Discussion
The goal of this study was to explore a novel strategy of inducing tumor-specific T-cell immunity in healthy donors, with transfer to recipients by bone marrow transplantation. The availability of a defined, tumor-specific antigen that is not expressed in normal tissues was essential to avoid autoimmunity in the donors and exacerbation of GVHD in recipients. Our results demonstrate that vaccination of HLA-matched, sibling BMT donors with myeloma-specific Id protein isolated from patients was safe and did not induce autoimmunity. Vaccination generally induced significant KLH-and Idspecific T-cell and antibody responses in all healthy donors, suggesting the feasibility of immunizing normal donors with healthy immune systems against both foreign and tumor-specific antigens. In contrast, neither Id-specific cellular nor humoral immunity was apparent in any of the five patients following parallel pre BMT immunizations with the same vaccines (Figure 4) . These results and the delayed immune reconstitution in the recipients following allogeneic BMT 31 and iatrogenic immunosuppressants used to prevent or control GVHD, provide justification for vaccinating the donors prior to bone marrow harvest as opposed to vaccinating the recipients alone in the immediate post transplant period. However, the requirement for multiple immunizations to induce Id-specific immunity, as opposed to a single immunization for KLH, may imply that some immune tolerance may exist against this tumor antigen even in healthy donors (Figure 2) .
Transfer of KLH-specific T-cell immunity from donor to recipient was clearly shown in patients R1 and R5 ( Figure  3a and c) and transfer of humoral immunity in-patient R5 (Figure 3b ). The KLH-specific immune responses in all three recipients that survived BMT appear to have been enhanced by booster immunizations (Figure 3a-e) . In contrast to KLH responses, Id-specific T-cell responses were detected only after booster immunizations in all three recipients. However, the detection of Id-specific T-cell responses after only one booster vaccination (Figure 4 and 5), suggests the rapid expansion of donor-derived Idprimed T-cell clones that may have been present following BMT albeit at frequencies too low to be detected by our assay. While not definitive, this result may imply the possible transfer of Id-primed T cells from the donors to the recipients, given the fact that induction of Id-specific immunity in healthy donors required three vaccinations (Figure 2b-d ). This conclusion is further supported by the observation that recipient R1 had 100% donor lymphoid chimerism prior to the post-BMT booster vaccination. In at least one patient, the Id-specific T-cell immunity persisted beyond 18 months after the completion of the vaccinations (Figure 4a) .
Given the small number of patients, it is not possible to draw conclusions regarding clinical outcome. However, the long duration of complete remissions in all three patients surviving the BMT procedure suggests that this strategy warrants exploration in larger clinical trials. Since the high transplant-related mortality (TRM) of up to 50% in myeloma patients following myeloablative allogeneic BMT [5] [6] [7] (two out of five in this trial) is an obstacle, evaluation of donor vaccination in the context of nonmyeloablative allogeneic peripheral blood stem cell transplant, which was shown to reduce the TRM to less than 10-20% in this patient population, 32 is warranted. An added potential benefit of a peripheral blood stem cell graft is the enhanced likelihood of transferring T-cell immunity and rapid donor lymphoid engraftment due to the presence of higher percentage of T cells compared with a bone marrow graft.
To conclude, this trial demonstrates that it is possible to safely induce tumor antigen-specific immunity in the donors and transfer it to allotransplant recipients to enhance the specific antitumor effect of the graft. Additional characterization of the induced T-cell responses in the donors in future trials for precursor frequency, memory T-cell induction, cytotoxic function, etc may better define the optimal schedule for vaccination and timing for harvest of the stem cell graft. Similarly, assessing the precursor frequency and in vivo persistence of the transferred tumor antigen-specific T cells will help in defining the role of booster immunizations in the recipients. The value of donor lymphocyte infusions in the context of donor vaccination also needs to be evaluated in future studies. Other groups are also currently evaluating this strategy of donor immunization in myeloma patients. 33 Finally, it may be feasible to extend this strategy to other hematologic malignancies and solid tumors for which defined tumorspecific antigens exist.
